摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Acetyl-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran | 65018-70-4

中文名称
——
中文别名
——
英文名称
6-Acetyl-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran
英文别名
6-Acetyl-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-1-benzopyran;6-acetyl-2,2-dimethyl-3,4-epoxychromane;6-acetyl-3,4-epoxy-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran;1-(2,2-dimethyl-1a,7b-dihydrooxireno[2,3-c]chromen-6-yl)ethanone
6-Acetyl-3,4-dihydro-2,2-dimethyl-3,4-epoxy-2H-benzo[b]pyran化学式
CAS
65018-70-4
化学式
C13H14O3
mdl
——
分子量
218.252
InChiKey
HHPHMEFAEUXBAX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    38.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    4-(取代-羰基氨基)-2H-1-苯并吡喃的合成及降压活性。
    摘要:
    描述了口服给予有意识的自发性高血压大鼠的一系列新型4-(取代-羰基氨基)-2H-1-苯并吡喃-3-醇的合成和降压活性。对于具有在羰基侧翼的烷基,氨基或芳基的化合物,观察到最佳活性。在烷基和氨基系列中,最有效的化合物分别包含甲基和甲基氨基。已使用-86作为标记物,将几种类似物与cromakalim(1)对兔肠系膜动脉钾离子外流的作用进行了比较。每种化合物增强rub 86流出的能力与其降血压活性大致平行​​,因此这些类似物(如化合物(1))属于已归类为钾通道激活剂的一系列药物。
    DOI:
    10.1021/jm00171a051
  • 作为产物:
    参考文献:
    名称:
    取代的反式-4-氨基-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3-醇的合成及降压活性。
    摘要:
    制备了一系列新型取代的反式-4-氨基-3,4-二氢-2,2-二甲基-2H-1-苯并吡喃-3-醇,并在有意识的乙酸脱氧皮质酮(DOCA)/盐水处理中测试了其降压活性。高血压大鼠。最佳的降血压活性需要一个强的吸电子基团与6位上的吡咯烷基或哌啶子基团一起进行6位取代。7-硝基-4-吡咯烷类似物和6-硝基-3-氯丙胺的例外,它们保留了明显的降压活性。所有这些化合物都是直接的血管扩张药,并且具有与肼屈嗪和钙拮抗剂硝苯地平相当的降压活性。这些化合物的合成路线包括将炔丙基醚环化为2H-1-苯并吡喃,然后通过溴代醇转化为3,4-环氧化物,用适当的胺开环。间取代的炔丙基醚在热环化反应中同时产生5-和7-取代的苯并吡喃,前者占优势。描述了一种新的制备2,2-二甲基-7-硝基苯并吡喃的途径。
    DOI:
    10.1021/jm00365a007
点击查看最新优质反应信息

文献信息

  • 2,2-dimethylchromene derivatives, process for their preparation and
    申请人:——
    公开号:US05391751A1
    公开(公告)日:1995-02-21
    The present invention relates to 2,2-dimethylchromene derivatives of the formula: ##STR1## in which Z represents a halogen atom or a cyano, nitro, acetyl, phosphono or dialkoxyphosohoryl group, the alkoxy group containing 1 to 3 carbon atoms, and the pharmaceutically acceptable salts of the phosphono group. These compounds show an antihypertensive and antiarrythmic activity. The present invention also relates to a process for the preparation of said compounds and to the pharmaceutical compositions in which the are present.
    本发明涉及公式为:##STR1##的2,2-二甲基香豆素衍生物,其中Z代表卤素原子或氰基、硝基、乙酰基、膦酸酯或二烷氧基膦基团,烷氧基团含有1至3个碳原子,并且磷酸酯基的药用盐。这些化合物表现出抗高血压和抗心律失常活性。本发明还涉及一种制备上述化合物的方法以及它们存在的药物组合物。
  • Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans
    作者:Valerie A. Ashwood、Robin E. Buckingham、Frederick Cassidy、John M. Evans、Erol A. Faruk、Thomas C. Hamilton、David J. Nash、Geoffrey Stemp、Kenneth Willcocks
    DOI:10.1021/jm00161a011
    日期:1986.11
    administered orally to conscious spontaneously hypertensive rats, are described. The effects of lactam ring size, the presence of heteroatoms in the lactam ring, substitution at C(2) and C(3), relative stereochemistry at C(3) and C(4), and aromatic substitution pattern on the blood pressure lowering activity of this series have been determined. The key compound 2 from this work [BRL 34915; (+/-)-6-cyano-3,4-dihydro-2
    描述了口服给有意识的自发性高血压大鼠的一系列新型4-(环酰胺基)-2H-1-苯并吡喃-3-醇的合成和降压活性。内酰胺环大小,内酰胺环中杂原子的存在,在C(2)和C(3)处的取代,在C(3)和C(4)处的相对立体化学以及芳香族取代模式对血压降低的影响该系列的活性已经确定。这项工作的关键化合物2 [BRL 34915; ((+/-)-6-氰基-3,4-二氢-2,2-二甲基-反-4-(2-氧吡咯烷-1-基)-2H-1-苯并吡喃-3-醇]已经解决,发现降压活性主要存在于(-)对映体中。制备这类化合物的关键步骤是环酰胺阴离子对适当环氧化物的作用。另一种方法
  • Benzopyrans
    申请人:Beecham Group p.l.c.
    公开号:US04446113A1
    公开(公告)日:1984-05-01
    Compounds of formula (I): ##STR1## wherein: one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, alkylsulphinyl, alkylsulphonyl, alkoxysulphinyl, alkoxysulphonyl, alkylcarbonylamino, alkoxycarbonylamino, or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two alkyl groups, or alkylsulphinylamino, alkylsulphonylamino, alkoxysulphinylamino or alkoxysulphonylamino, or ethylenyl terminally substituted by alkylcarbonyl, nitro or cyano or --C(alkyl)NOH or --C(alkyl)NNH.sub.2, the alkyl groups or alkyl moieties of alkyl-containing groups having from 1 to 6 carbon atoms; one of R.sub.3 and R.sub.4 is hydrogen or alkyl having from 1 to 4 carbon atoms and the other is alkyl having from 1 to 4 carbon atoms, or R.sub.3 and R.sub.4 together with the carbon atom to which they are attached are spiroalkyl having from 3 to 6 carbon atoms; R.sub.5 is hydrogen, alkyl having from 1 to 3 carbon atoms or acyl having from 1 to 8 carbon atoms; and n is 1 or 2; the lactam group being trans to the OR.sub.5 group; have anti-hypertensive activity and are of use in the treatment of high blood pressure.
    式(I)的化合物:其中:R.sub.1和R.sub.2中的一个是氢,另一个选自烷基羰基、烷氧羰基、烷基羟基甲基、硝基、氰基、氯基、三氟甲基、烷基砜基、烷基磺酰基、烷氧基砜基、烷氧基磺酰基、烷基羰胺基、烷氧羰胺基,或氨基砜基、氨基磺酰基或氨基羰基类别,氨基团可选地被一个或两个烷基基团取代,或者烷基砜基氨基、烷基磺酰基氨基、烷氧基砜基氨基或烷氧基磺酰基氨基,或者末端取代为烷基羰基、硝基或氰基或--C(烷基)NOH或--C(烷基)NNH.sub.2的乙烯基,烷基含有1至6个碳原子的烷基基团;R.sub.3和R.sub.4中的一个是氢或含有1至4个碳原子的烷基,另一个是含有1至4个碳原子的烷基,或者R.sub.3和R.sub.4与它们连接的碳原子一起是含有3至6个碳原子的螺环烷基;R.sub.5是氢、含有1至3个碳原子的烷基或含有1至8个碳原子的酰基;n为1或2;内酰胺基团位于OR.sub.5基团的反位;具有降压活性,并可用于治疗高血压。
  • Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators
    作者:Rolf Bergmann、Rolf Gericke
    DOI:10.1021/jm00164a005
    日期:1990.2
    other heterocycles such as 4-pyridone, pyrimidone, pyridazinone, pyrazinone, and 1,4-butanesultam, the activity is maintained. The removal of the 3-hydroxy function (----17a) does not significantly reduce the activity. The elimination of water from the chromanols leads to the formation of the chromenes, which are among the most potent antihypertensives known. The influence of diverse substituents, in
    描述了4-(1,2-二氢-2-氧代-1-吡啶基)-2H-1-苯并吡喃-3-醇的合成和降压活性。未取代的吡啶酮加合物铅化合物7e具有高活性,吡啶酮环上的取代基导致活性降低。为了获得最佳活性,必须在C-6位上强烈吸电子的取代基。当2-吡啶酮环被其他杂环如4-吡啶酮,嘧啶酮,哒嗪酮,吡嗪酮和1,4-丁烷磺胺取代时,活性得以维持。3-羟基官能团(---- 17a)的去除不会显着降低活性。从苯并二氢吡喃醇中除去水会导致苯并二氢吡喃酮的形成,这是已知最有效的降压药之一。各种取代基,尤其是杂环C-6取代基的影响,以4-(2-氧代-1-吡咯烷基)色满-3-醇系列进行了研究。铬醇在3-羟基处被短链酸酯化,保持其活性。色烯双键的环氧化也产生活性化合物。环氧化物22的重排产生3-酮化合物23和烯醇衍生物25。酮23a的还原产生顺式-苯并二氢吡喃醇7ab及其反式异构体7e。在自发性高血压大鼠中以1 mg / kg
  • 4-Acylaminobenzopyrans useful as anti-hypertensive agents
    申请人:Beecham Group p.l.c.
    公开号:US04481214A1
    公开(公告)日:1984-11-06
    Compounds of formula (I): ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, C.sub.1-6 alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkylsulphinylamino, C.sub.1-6 alkylsulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or --C(C.sub.1-6 alkyl)NOH or --C(C.sub.1-6 alkyl)NNH.sub.2, or one of R.sub.1 and R.sub.2 is nitro, cyano or C.sub.1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C.sub.1-6 alkyl or by C.sub.2-7 alkanoyl; one of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-4 alkyl and the other is C.sub.1-4 alkyl or R.sub.3 and R.sub.4 together with the carbon atom to which they are attached are C.sub.2-5 polymethylene; either R.sub.5 is hydroxy, C.sub.1-6 alkoxy or C.sub.2-7 acyloxy and R.sub.6 is hydrogen or R.sub.5 and R.sub.6 together are a bond; R.sub.7 is hydrogen, C.sub.1-6 alkyl optionally substituted by hydroxy, C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl or carboxy, or C.sub.1-2 alkyl substituted by halogen, or C.sub.2-6 alkenyl; R.sub.8 is hydrogen or C.sub.1-6 alkyl; and X is oxygen or sulphur; the R.sub.8 --N--CX--R.sub.7 group being trans to the R.sub.5 group when R.sub.5 and R.sub.6 together are not a bond; or, when one or the other of R.sub.1 and R.sub.2 is an amino or an amino-containing group, a pharmaceutically acceptable salt thereof, having anti-hypertensive activity.
    式(I)的化合物:其中:R.sub.1和R.sub.2中的任意一个是氢,另一个选自C.sub.1-6烷基羰基,C.sub.1-6烷氧羰基,C.sub.1-6烷基羰氧基,C.sub.1-6烷基羟甲基,硝基,氰基,氯基,三氟甲基,C.sub.1-6烷基砜基,C.sub.1-6烷基磺酰基,C.sub.1-6烷氧基砜基,C.sub.1-6烷氧基磺酰基,C.sub.1-6烷基羰基氨基,C.sub.1-6烷氧羰基氨基,C.sub.1-6硫代烷基羰基,C.sub.1-6硫代烷氧基羰基,C.sub.1-6硫代烷基羰氧基,C.sub.1-6硫代烷硫基甲基,甲酰基或氨基砜基,氨基磺酰基或氨基羰基,氨基部分可选择地被一个或两个C.sub.1-6烷基基团取代,或C.sub.1-6烷基砜基氨基,C.sub.1-6烷基磺酰基氨基,C.sub.1-6烷氧基砜基氨基或C.sub.1-6烷氧基磺酰基氨基,或末端被C.sub.1-6烷基羰基,硝基或氰基取代的乙烯基,或--C(C.sub.1-6烷基)NOH或--C(C.sub.1-6烷基)NNH.sub.2,或R.sub.1和R.sub.2中的一个是硝基,氰基或C.sub.1-3烷基羰基,另一个是甲氧基或氨基,可选择地被一个或两个C.sub.1-6烷基或C.sub.2-7烷酰基取代;R.sub.3和R.sub.4中的一个是氢或C.sub.1-4烷基,另一个是C.sub.1-4烷基或R.sub.3和R.sub.4与它们连接的碳原子一起是C.sub.2-5聚亚甲基;R.sub.5是羟基,C.sub.1-6烷氧基或C.sub.2-7酰氧基,R.sub.6是氢或R.sub.5和R.sub.6一起是键合;R.sub.7是氢,C.sub.1-6烷基,可选择地被羟基,C.sub.1-6烷氧基,C.sub.1-6烷氧羰基或羧基取代,或被卤素取代的C.sub.1-2烷基,或C.sub.2-6烯基;R.sub.8是氢或C.sub.1-6烷基;X是氧或硫;当R.sub.5和R.sub.6一起不是键合时,R.sub.8--N--CX--R.sub.7基与R.sub.5基是反式的;或者,当R.sub.1和R.sub.2中的一个是氨基或含氨基的基团时,其药学上可接受的盐,具有抗高血压活性。
查看更多